KEY FEATURES
| Full Name | Adenylyl Cyclase Associated Protein 1 |
|---|---|
| Synonym | CAP; CAP1-PEN |
| Assay Type | Sandwich |
| Reactivity | Human |
| Range | 0.15-10ng/mL |
| Sensitivity | 0.07ng/mL |
| Sample Type | Serum,plasma and other biological fluids |
| Sample Volume | 100μL |
| Detection Wavelength | OD450 |
| Transportation Temperature | 2-8°C |
| Specificity | The kit detected Human CAP1 in the samples and no significant cross-species reactions were found |
| Microplate | 96-wells plate breakable into 12 x 8 wells strip |
TEST PRINCIPLE
| This ELISA kit uses the Sandwich-ELISA principle. The micro ELISA plate provided in this kit has been pre-coated with an antibody specific to Human CAP1. Standards or samples are added to the micro ELISA plate wells and combined with the specific antibody. Then a biotinylated detection antibody specific for Human CAP1 and Avidin-Horseradish Peroxidase (HRP) conjugate are added successively to each micro plate well and incubated. Free components are washed away. The substrate solution is added to each well. Only those wells that contain Human CAP1, biotinylated detection antibody and Avidin-HRP conjugate will appear blue in color. The enzyme-substrate reaction is terminated by the addition of stop solution and the color turns yellow. The optical density (OD) is measured spectrophotometrically at a wavelength of 450 nm ± 2 nm. The OD value is proportional to the concentration of Human CAP1. You can calculate the concentration of Human CAP1 in the samples by comparing the OD of the samples to the standard curve. |
ELISA KIT COMPONENTS
Upon receipt, unpack promptly and store as recommended in the instructions.
| Components | Specifications | Storage and Notes |
|---|---|---|
| Micro Plate | 96T: 8 wells×12 strips 48T: 8 wells×6 strips | Unopened: -20°C, 12 months Unused: Put it back in the aluminum foil bag and seal it, store it at -20°C. |
| Reference Standard | 96T: 2 vials 48T: 1 vial | Unopened: -20°C, 12 months Please use freshly dissolved standards for each experiment. Discard any unused standards after dissolution. |
| Biotinylated Detection Ab Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C, 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| HRP Conjugate Concentrate (100×) | 96T: 120μL×1 vial 48T: 60μL×1 vial | Unopened: -20°C(Protect from light), 12 months Unused: Please seal the concentrate and store it at -20°C, and discard the working solution. |
| Biotinylated Detection Ab Diluent | 14mL×1 | 2-8℃, 12 months |
| HRP Conjugate Diluent | 14mL×1 | 2-8℃, 12 months |
| Reference Standard & Sample Diluent | 20mL×1 | 2-8℃, 12 months |
| Washing Buffer Concentrate (25×) | 30mL×1 | 2-8℃, 12 months |
| Substrate Reagent(TMB) | 10mL×1 | 2-8°C(Protect from light),12 months |
| Stop Solution | 7mL×1 | 2-8°C/Room temperature |
ASSAY PROCEDURES
TYPICAL DATA
Human CAP1 ELISA Standard Curve
Typical data are for reference only and curves should be replotted for each experiment. The Logistics function is recommended for fitting.
PRECISION
Intra-Assay Precision (Precision within an assay): Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-Assay Precision (Precision between assays): Three samples of known concentration were tested in twenty separate assays to assess inter-assay precision. Assays were performed by at least three technicians using two lots of components.
| Intra-assay Precision | Inter-assay Precision | |||||
|---|---|---|---|---|---|---|
| Sample | 1 | 2 | 3 | 1 | 2 | 3 |
| n | 20 | 20 | 20 | 20 | 20 | 20 |
| Mean (ng/mL) | 0.53 | 1.17 | 4.3 | 0.56 | 1.1 | 4.67 |
| Standard deviation | 0.03 | 0.05 | 0.17 | 0.03 | 0.06 | 0.21 |
| CV(%) | 6.38 | 4.23 | 4.06 | 5.88 | 5.25 | 4.55 |
RECOVERY
The recovery of Human CAP1 spiked to three different levels in samples throughout the range of the assay in various matrices was evaluated.
| Sample Type | Range (%) | Average Recovery (%) |
|---|---|---|
| Serum(n=8) | 86-99 | 91 |
| EDTA plasma (n=8) | 88-100 | 93 |
| Cell culture media (n=8) | 95-108 | 101 |
LINEARITY
To assess the linearity of the assay, samples containing and/or spiked with high concentrations of Human CAP1 in various matrices were diluted with the Reference Standard & Sample Diluent to produce samples with values within the dynamic range of the assay.
Products associated with SCF ELISA Kits
| KIT antibody | publications with SCF and KIT |
| STAT3 antibody | publications with SCF and STAT3 |
| JAK2 antibody | publications with SCF and JAK2 |
| EPOR antibody | publications with SCF and EPOR |
| GRB2 antibody | publications with SCF and GRB2 |
| LYN antibody | publications with SCF and LYN |
| FER antibody | publications with SCF and FER |
| CSF2 antibody | publications with SCF and CSF2 |
| MATK antibody | publications with SCF and MATK |
Pathways associated with SCF ELISA Kit
| Adaptive Immune System Pathway | Adaptive Immune System Pathway |
| C-MYB Transcription Factor Network Pathway | C-MYB Transcription Factor Network Pathway |
| Cell Cycle Pathway | Cell Cycle Pathway |
| Constitutive PI3K/AKT Signaling In Cancer Pathway | Constitutive PI3K/AKT Signaling In Cancer Pathway |
| Cytokine-cytokine Receptor Interaction Pathway | Cytokine-cytokine Receptor Interaction Pathway |
| DAP12 Interactions Pathway | DAP12 Interactions Pathway |
| DAP12 Signaling Pathway | DAP12 Signaling Pathway |
| Disease Pathway | Disease Pathway |
| Downstream Signaling Events Of B Cell Receptor (BCR) Pathway | Downstream Signaling Events Of B Cell Receptor (BCR) Pathway |
Diseases associated with SCF ELISA Kit
| Necrosis | publications with SCF and Necrosis |
| Cardiovascular Diseases | publications with SCF and Cardiovascular Diseases |
| Bone Marrow Diseases | publications with SCF and Bone Marrow Diseases |
| Nervous System Diseases | publications with SCF and Nervous System Diseases |
| Carcinoma | publications with SCF and Carcinoma |
| Inflammation | publications with SCF and Inflammation |
| Neoplasms, Germ Cell and Embryonal | publications with SCF and Neoplasms, Germ Cell and Embryonal |
| Heart Diseases | publications with SCF and Heart Diseases |
| Drug Toxicity | publications with SCF and Drug Toxicity |
| Breast Neoplasms | publications with SCF and Breast Neoplasms |
Organs/Tissues associated with SCF ELISA Kit
| Blood | publications with SCF and Blood |
| Bone | publications with SCF and Bone |
| Vascular | publications with SCF and Vascular |
| Brain | publications with SCF and Brain |
| Embryonic Tissue | publications with SCF and Embryonic Tissue |
| Muscle | publications with SCF and Muscle |
| Nerve | publications with SCF and Nerve |
| Liver | publications with SCF and Liver |
| Connective Tissue | publications with SCF and Connective Tissue |
| Skin | publications with SCF and Skin |
